Blood glucose fluctuations in type 2 diabetes patients treated with multiple daily injections

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  Li, Feng Fei ^a   Fu, Li Yuan ^b   Zhang, Wen Li ^a   Su, Xiao Fei ^a   Wu, Jin Dan ^a   Sun, Jin ^a   Ye, Lei ^c   Ma, Jian Hua ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c DEPARTMENT OF CARDIOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN ASPART; INSULIN GLARGINE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; BIPHASIC INSULIN; GLUCOSE BLOOD LEVEL; INSULIN ASPART, INSULIN ASPART PROTAMINE DRUG COMBINATION 30:70; ISOPHANE INSULIN;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; BLOOD GLUCOSE MONITORING; CONTINUOUS SUBCUTANEOUS INSULIN INFUSION; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN INTENSIVE THERAPY; INSULIN TREATMENT; INTENSIVE CARE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MULTICENTER STUDY; MULTIPLE DAILY INJECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; BLOOD; CHINA; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; HOSPITALIZATION; INSULIN INFUSION; METABOLISM; MIDDLE AGED; PILOT STUDY; PROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; TIME FACTOR;

ADULT; AGED; BIOMARKERS; BIPHASIC INSULINS; BLOOD GLUCOSE; CHINA; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, SUBCUTANEOUS; INJECTIONS, SUBCUTANEOUS; INSULIN ASPART; INSULIN GLARGINE; INSULIN INFUSION SYSTEMS; INSULIN, ISOPHANE; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84957090643     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/1028945     Document Type: Article

References (20)

1. M. Riddle, G. Umpierrez, A. DiGenio et al. , "Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes," Diabetes Care, vol. 34, pp. 2508-2514, 2011.
2. H. Ilkova, B. Glaser, A. Tunckale, N. Bagriacik, and E. Cerasi, "Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment," Diabetes Care, vol. 20, no. 9, pp. 1353-1356, 1997.
3. Y. Li, W. Xu, Z. Liao et al. , "Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of β-cell function," Diabetes Care, vol. 27, no. 11, pp. 2597-2602, 2004.
4. R. Retnakaran and D. J. Drucker, "Intensive insulin therapy in newly diagnosed type 2 diabetes," The Lancet, vol. 371, no. 9626, pp. 1725-1726, 2008.
5. E. A. Ryan, S. Imes, and C. Wallace, "Short-term intensive insulin therapy in newly diagnosed type 2 diabetes," Diabetes Care, vol. 27, no. 5, pp. 1028-1032, 2004.
6. R. Retnakaran, N. Yakubovich, Y. Qi, C. Opsteen, and B. Zinman, "The response to short-term intensive insulin therapy in type 2 diabetes," Diabetes, Obesity & Metabolism, vol. 12, no. 1, pp. 65-71, 2010.
7. Y. Reznik, O. Cohen, R. Aronson et al. , "Insulin pump treatment compared with multiple daily injections for treatment of type diabetes (OpT2mise): a randomised open-label controlled trial," The Lancet, vol. 384, no. 9950, pp. 1265-1272, 2014.
8. J. Weng, Y. Li, W. Xu et al. , "Effect of intensive insulin therapyon beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallelgroup trial," The Lancet, vol. 371, no. 9626, pp. 1753-1760, 2008.
9. J. Zhou, H. Li, X. Ran et al. , "Reference values for continuous glucose monitoring in Chinese subjects," Diabetes Care, vol. 32, no. 7, pp. 1188-1193, 2009.
10. F. J. Service, G. D. Molnar, J. W. Rosevear, E. Ackerman, L. C. Gatewood, and W. F. Taylor, "Mean amplitude of glycemic excursions, a measure of diabetic instability," Diabetes, vol. 19, no. 9, pp. 644-655, 1970.
11. D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, "Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man," Diabetologia, vol. 28, no. 7, pp. 412-419, 1985.
12. G. Daniele, R. Guardado Mendoza, D. Winnier et al. , "The inflammatory status score including IL-6, TNF-α;, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus," Acta Diabetologica, vol. 51, no. 1, pp. 123-131, 2014.
13. D. LeRoith, V. Fonseca, and A. Vinik, "Metabolic memory in diabetes-focus on insulin," Diabetes/Metabolism Research and Reviews, vol. 21, no. 2, pp. 85-90, 2005.
14. J. Wainstein, M. Metzger, M. Boaz et al. , "Insulin pump therapy vs. multiple daily injections in obese Type 2 diabetic patients," Diabetic Medicine, vol. 22, no. 8, pp. 1037-1046, 2005.
15. E. Boland, T. Monsod, M. Delucia, C. A. Brandt, S. Fernando, and W. V. Tamborlane, "Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes," Diabetes Care, vol. 24, no. 11, pp. 1858-1862, 2001.
16. DECODE Study Group, "Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria," Archives of Internal Medicine, vol. 161, no. 3, pp. 397-405, 2001.
17. M. Coutinho, H. C. Gerstein, Y. Wang, and S. Yusuf, "The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95, 783 individuals followed for 12. 4 years," Diabetes Care, vol. 22, no. 2, pp. 233-240, 1999.
18. M. Brownlee, "The pathobiology of diabetic complications: a unifying mechanism," Diabetes, vol. 54, no. 6, pp. 1615-1625, 2005.
19. K. Esposito, F. Nappo, R. Marfella et al. , "Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress," Circulation, vol. 106, no. 16, pp. 2067-2072, 2002.
20. W. Jia, X. Xiao, Q. Ji et al. , "Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial," The Lancet Diabetes & Endocrinology, vol. 3, pp. 254-262, 2015.